Abstract library

1077 results for "clinical assay".
#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations
Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: Dr Anguraj Sadanandam
#1107 The Chicken Chorioallantoic Membrane Assay as a Preclinical Model for the Research of Rare Gastrointenstinal Neuroendocrine Tumours
Introduction: Preclinical trials of cancer therapeutics require both in vitro and in vivo evaluations. For neuroendocrine tumours (NET) studies are limited to cell lines, thus xenograft models are needed for screening and evaluation of anti-cancer drugs. The chick chorioallantoic membrane (CAM) assay is a well-established model system to investigate tumour growth, angiogenesis and metastasis.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: ...none of the below
Presenting Author: PhD Nassim Ghaffari Tabrizi-Wizsy
Authors: Passegger C, Kump P, Haybäck J, Lipp R, ...
#783 A Comparison of Three Chromogranin A Assays in Patients with Neuroendocrine Tumors
Introduction: Chromogranin A (CgA) is the most important general tumor marker used in the diagnosis and follow-up of patients with neuroendocrine tumors (NET). CgA assays may have different sensitivities, which is of importance for the clinical diagnosis and handling of NET patients.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Biomarkers
Presenting Author: Dr. Henning Grønbæk
#2910 Virotherapy Shows Promising Efficacy in Neuroendocrine Cancers
Introduction: So far, there have been only two clinical studies using virotherapeutics to treat neuroendocrine cancers (NCT00314925 & NCT02749331). Notably, none of these approaches employed a clinically approved virotherapeutic compound.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Prof. Ulrich M. Lauer
#448 Comparison of the Automated Chromogranin A Assay Using KRYPTOR Instrumentation with the Manual IRMA Assay of CisBio
Introduction: Chromogranin A (CgA) has become the most important tumor marker for neuroendocrine tumors (NET) during the last decade. To meet the need for high throughput and rapid measurements, the fully automated Thermo Scientific BRAHMS KRYPTOR CgA assay has been developed.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Catharina M Korse
Authors: Korse C M, Baan A W, Tesselaar M E, ...
#844 Variation Between Chromogranin A Assays in the Diagnosis of Gastric Carcinoid Type 1
Introduction: Chromogranin A (CgA) is not very accurate for the diagnosis of gastric carcinoid type1 (GC1). Clinical interpretation of CgA results may be affected by the heterogeneity between CgA assays. The commercial CgA assay, DAKO (DAKO, Denmark A/S, Glostrup, Denmark) is an ELISA which recognizes a 23 kD C terminal fragment of CgA; the Imperial Supra-regional Assay Service radioimmunoassay (SAS Hammersmith Hospital, Imperial College, London) is a competitive radioimmunoassay raised against the whole pancreastatin molecule.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: MD Roberta E Rossi
#1177 An Isolated Abnormal Chromogranin B Is Associated with Pancreato-Duodenal NETs and the Presence of Liver Metastases
Introduction: Chromogranin B (CgB) is a soluble secretory protein like chromogranin A (CgA) that has been reported to be elevated in patients with neuroendocrine tumours (NETs) but is not routinely assessed.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Ron Basuroy
#68 Serum chromogranin A as tumor marker in neuroendocrine tumors
Introduction: Serum chromogranin A (CgA) is used as a tumor marker for neuroendocrine tumors (NETs).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Svenja Nölting
#2294 Identification and Validation of the Angiotensin II Receptor Type 1 as a Possible Anti-Cancer Target in Neuroendocrine Tumors
Introduction: Neuroendocrine tumours (NETs) have been found to overexpress somatostatin receptors (SSTRs), which led to the development of somatostatin analogs utilized for diagnostics and therapeutics. However, around 30% of all NETs do not respond to somatostatin based approaches, leading to an interest to find and characterize alternative cell surface targets.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Carsten Grötzinger
#299 Clinical and Immunohistochemical Evaluation of Medullary Thyroid Cancer (MTC) and C Cell Hyperplasia (CCH)
Introduction: MTC and CCH has a variable clinical presentation and prognosis and no data are available on the correlation between immunoistochemical (IIC) characterization and clinical behavior.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Prof Laura De Marinis
Authors: Lugli F, Fusco A, Bianchi A, Milardi D, ...